Controlling in and out - the future of interfering with immune cell trafficking in inflammatory bowel disease

Zundler S, Schulze L, Neurath M (2022)

Publication Type: Journal article, Review article

Publication year: 2022

Journal

Expert Review of Clinical Immunology Expert Reviews (formerly Future Drugs)

DOI: 10.1080/1744666X.2023.2152794

Abstract

IntroductionImmune cell trafficking is a key requirement in the pathogenesis of inflammatory bowel diseases. Consistently, therapeutic strategies to target immune cell trafficking have been established and continue to be developed for the treatment of ulcerative colitis and Crohn's disease.Areas coveredIn this review, we briefly summarize the most important checkpoints of intestinal immune cell trafficking and their importance during IBD. Moreover, we provide an overview of associated therapeutic targets and previous as well as current efforts on treatment strategies related to these targets.Expert opinionFinally, we comment on potential future developments that might shape the field of immune cell trafficking in the context of IBD.

Authors with CRIS profile

Sebastian Zundler Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Lisa Schulze Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Markus Neurath Lehrstuhl für Innere Medizin I

How to cite

APA:

Zundler, S., Schulze, L., & Neurath, M. (2022). Controlling in and out - the future of interfering with immune cell trafficking in inflammatory bowel disease. Expert Review of Clinical Immunology. https://doi.org/10.1080/1744666X.2023.2152794

MLA:

Zundler, Sebastian, Lisa Schulze, and Markus Neurath. "Controlling in and out - the future of interfering with immune cell trafficking in inflammatory bowel disease." Expert Review of Clinical Immunology (2022).

BibTeX: Download